Mein Warenkorb

HMGB1

HMGB1 Molekülinformation

Englischer NameHigh Mobility Group Protein B1Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1Target-AliasFM1 Gene Product,HMG 1 Protein,HMG-1 Protein,HMG1,Heparin-Binding Protein p30,High Mobility Group Box 1,High-Mobility Group (Nonhistone Chromosomal) Protein 1,High Mobility Group Protein B1,High Mobility Group Protein 1,HMG-1,Sulfoglucuronyl Carbohydrate Binding Protein,Amphoterin,Box Protein 1, High Mobility Group,SBP-1,High-Mobility Group Box 1,DKFZp686A04236,HMGB1
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameHigh Mobility Group Protein B1
Target-AliasFM1 Gene Product,HMG 1 Protein,HMG-1 Protein,HMG1,Heparin-Binding Protein p30,High Mobility Group Box 1,High-Mobility Group (Nonhistone Chromosomal) Protein 1,High Mobility Group Protein B1,High Mobility Group Protein 1,HMG-1,Sulfoglucuronyl Carbohydrate Binding Protein,Amphoterin,Box Protein 1, High Mobility Group,SBP-1,High-Mobility Group Box 1,DKFZp686A04236,HMGB1
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

HMGB1 Produktliste

  • Attribut

    Protein (4)

  • Produktbibliothek

    Online (4)

  • Spezies

    Human (3)Mouse (1)

  • Etikett

    His Tag (2)Mouse IgG Fc Tag (1)His Tag & Avi Tag (1)

  • Marker

    Unconjugated (3)Biotin-labeled (1)

HMGB1 Molekülhintergrund

High-mobility group protein B1 (HMGB1) is also known as high-mobility group protein 1 (HMG-1) and amphoterin, is a member of the HMGB family consisting of three members, HMGB1, HMGB2 and HMGB3. HMGB1 is a non-histone architectural chromosomal protein ubiquitously present in all vertebrate nuclei and binds double-stranded DNA without sequence specificity. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. This positions HMGB1 at the intersection of sterile and infectious inflammatory responses. HMGB1 has been studied as a DNA vaccine adjuvant and a target for cancer therapy.

HMGB1 Molekülalias

HMGB1,HMG1,HMG3,SBP-1

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
SB-17170SB-17170Phase 2 ClinicalSpark Biopharma IncDrug-Related Side Effects and Adverse Reactions; Idiopathic Pulmonary Fibrosis; Solid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns